Rapamycin Extends Life Span in Apc Colon Cancer FAP Model
Open Access
- 15 September 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (1), e61-e70
- https://doi.org/10.1016/j.clcc.2020.08.006
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 37 references indexed in Scilit:
- mTOR at the nexus of nutrition, growth, ageing and diseaseNature Reviews Molecular Cell Biology, 2020
- A Kinase Inhibitor Targeted to mTORC1 Drives Regression in GlioblastomaCancer Cell, 2017
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorNature, 2016
- Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restrictionAging Cell, 2014
- Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in MiceScience Signaling, 2012
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT SignalingCancer Discovery, 2011
- Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous MiceThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2010
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Common corruption of the mTOR signaling network in human tumorsOncogene, 2008